 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | SARS-CoV-2 convalescent plasma / French Defence Health Service Headquarters
Enrollment change, Trial termination: PLASCOSSA: Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (clinicaltrials.gov) - Apr 14, 2022
P3, N=18, Terminated, Sponsor: Direction Centrale du Service de Santé des Armées
New variants have appeared since the plasma collection period. Some recent publications question the effectiveness of transfusion.
- | SARS-CoV-2 convalescent plasma / French Defence Health Service Headquarters
Enrollment open, Trial initiation date, Trial primary completion date: PLASCOSSA: Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (clinicaltrials.gov) - Oct 26, 2020
P3, N=80, Recruiting, Sponsor: Direction Centrale du Service de Santé des Armées
Some recent publications question the effectiveness of transfusion. Not yet recruiting --> Recruiting | Initiation date: May 2020 --> Sep 2020 | Trial primary completion date: Oct 2020 --> May 2021
- | SARS-CoV-2 convalescent plasma / French Defence Health Service Headquarters
New P3 trial: PLASCOSSA: Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients. (clinicaltrials.gov) - May 4, 2020
P3, N=80, Not yet recruiting, Sponsor: Direction Centrale du Service de Santé des Armées